BAYER DIAGNOSTICS ADDS CEA ASSAY TO TECHNICON CANCER TEST PANEL WITH JAN. 30 PMA APPROVAL; THREE CA ASSAYS LICENSED FROM CENTOCOR IN FIRM'S PIPELINE
This article was originally published in The Gray Sheet
Executive SummaryBayer Diagnostics added a second assay to its planned panel of six cancer tests on Jan. 30 with the approval of the Technicon Immuno 1 carcinoembryonic antigen (CEA) assay for monitoring cancer patients. The approval follows FDA clearance of the first test, a prostate specific antigen (PSA) assay, on Dec. 22.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.